NYSEAMERICAN:VNRXVolitionRX Stock Price, Forecast & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VolitionRX in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for VolitionRX.

VolitionRX is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for VolitionRX.

VolitionRX Ltd (NYSEAMERICAN:VNRX) issued its quarterly earnings results on Thursday, May, 7th. The medical research company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.04. The medical research company had revenue of $0.54 million for the quarter.
View VolitionRX's earnings history.

3 analysts have issued 1-year price objectives for VolitionRX's stock. Their forecasts range from $7.00 to $10.00. On average, they anticipate VolitionRX's stock price to reach $8.33 in the next twelve months. This suggests a possible upside of 153.3% from the stock's current price.
View analysts' price targets for VolitionRX.

Press coverage about VNRX stock has trended somewhat positive recently, according to InfoTrie. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. VolitionRX earned a news sentiment score of 1.8 on InfoTrie's scale. They also gave media headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term.
View the latest news about VolitionRX.

VolitionRX saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 544,700 shares, an increase of 26.3% from the June 15th total of 431,200 shares. Based on an average daily volume of 299,600 shares, the short-interest ratio is presently 1.8 days. Approximately 2.0% of the shares of the company are sold short.
View VolitionRX's Current Options Chain.

Some companies that are related to VolitionRX include Spectral Medical (EDT), ANGLE (AGL), Proteome Sciences (PRM), DiaSorin (DIA) and Premaitha Health (NIPT).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other VolitionRX investors own include (CHK), Bausch Health Companies (BHC), Verastem (VSTM), Bausch Health Companies (BHC), Ring Energy (REI), Ring Energy (REI), Crispr Therapeutics (CRSP), Exelixis (EXEL), Gilead Sciences (GILD) and ContraFect (CFRX).

VolitionRX trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "VNRX."

VolitionRX's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include UBS Group AG (0.03%). Company insiders that own VolitionRX stock include Cameron John Reynolds, Corp Ltd Eight, Guy Archibald Innes and Martin Charles Faulkes.
View institutional ownership trends for VolitionRX.

VNRX stock was bought by a variety of institutional investors in the last quarter, including UBS Group AG. Company insiders that have bought VolitionRX stock in the last two years include Cameron John Reynolds, Corp Ltd Eight, Guy Archibald Innes, and Martin Charles Faulkes.
View insider buying and selling activity for VolitionRX.

Shares of VNRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VNRX stock can currently be purchased for approximately $3.29.

VolitionRX has a market capitalization of $135.56 million. VolitionRX employs 44 workers across the globe.

The official website for VolitionRX is www.volitionrx.com.

The medical research company can be reached via phone at 646 650 1351.